Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ELOVL1 | Q9BW60 | 5/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1963305 | 0.85 | CYP11B2 (0.37) | SLC6A9KCNH2ELOVL1CYP11B2CYP11B1 | |
| SCHEMBL1962386 | 0.77 | FAAH (0.48) | SLC6A9KCNH2ELOVL1CYP11B2CYP11B1 | |
| SCHEMBL1961279 | 0.76 | ELOVL1 (0.43) | SLC6A9KCNH2ELOVL1CYP11B2CYP11B1 | |
| SCHEMBL12004678 | 0.70 | CYP11B2 (0.35) | SLC6A9KCNH2ELOVL1CYP11B2 | |
| SCHEMBL19120675 | 0.70 | ELOVL1 (0.36) | ELOVL1CYP11B2 | |
| SCHEMBL1961901 | 0.66 | ELOVL1 (0.43) | SLC6A9KCNH2ELOVL1CYP11B2CYP11B1 | |
| SCHEMBL1962427 | 0.64 | FAAH (0.47) | SLC6A9KCNH2ELOVL1CYP11B2CYP11B1 | |
| SCHEMBL1964385 | 0.64 | FAAH (0.49) | KCNH2 | |
| SCHEMBL19120755 | 0.64 | ELOVL1 (0.44) | ELOVL1CYP11B2 | |
| SCHEMBL26847571 | 0.61 | ELOVL1 (0.38) | SLC6A9KCNH2ELOVL1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2299824-B1 | PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME (US) | 2013-06-19 | — | — | EP | disclosed |
| EP-2299824-B1 | PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20110144056-A1 | PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. | 2011-06-16 | — | — | US | disclosed |
| US-20110144056-A1 | PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. | 2011-06-16 | — | — | US | disclosed |
| US-20110144056-A1 | PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144056-A1 | PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | FAAH, FAAH2, HRH2 | SLC6A9 4875/4885KCNH2 930/4885ELOVL1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.